News about Drug Discovery & Development

Amneal Pharma Gets US FDA Approval for CREXONT Extended-Release Capsules

CREXONT is a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release (IR) granules and extended-release (ER) pellets.

Drug Discovery & Development | 08/08/2024 | By Aishwarya |  998

Lupin Gets Approval from US FDA for Prednisolone Acetate Ophthalmic Suspension

Lupin has secured approval from US FDA for its Abbreviated New Drug Application (ANDA) for Prednisolone Acetate Ophthalmic Suspension USP, 1 percent to market a generic equivalent of Pred Forte Ophthalmic Suspension, 1 percent, of AbbVie Inc.

Drug Discovery & Development | 07/08/2024 | By Aishwarya |  778

Lupin Completes Phase 3 Trials for Lucentis Biosimilar

Lupin has successfully completed a global Phase 3 clinical study of LUBT010, its biosimilar candidate to Lucentis.

Drug Discovery & Development | 06/08/2024 | By Aishwarya |  748

Alembic Pharma Gets USFDA Final Approval for Nelarabine Injection

Alembic Pharmaceuticals has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Nelarabine Injection, 250 mg/50 mL (5 mg/mL) (Single-Dose Vial).

Drug Discovery & Development | 05/08/2024 | By Aishwarya |  772

Inoviv Introduces MasterKey for Multiplexed Targeted Protein Assays

Inoviv has developed MasterKey, which enables researchers to select specific proteins from a comprehensive, pre-characterized catalog of thousands of proteins.

Drug Discovery & Development | 01/08/2024 | By Aishwarya |  694

Zydus Gets Approval from COFEPRIS to Market Mamitra

Zydus Lifesciences has announced that COFEPRIS (Federal Commission for the Protection Against Sanitary Risk) has granted marketing approval for Mamitra, a Trastuzumab biosimilar.

Drug Discovery & Development | 31/07/2024 | By Aishwarya |  873

OneSource Signs Licensing Deal with BRL to Deliver High-Concentration Biologic Products

OneSource Specialty Pharma Ltd. has signed a strategic licensing agreement with Bhami’s Research Laboratory (BRL).

Drug Discovery & Development | 30/07/2024 | By Aishwarya |  888

Luye Pharma Gets US FDA Approval of ERZOFRI Extended-Release Injectable Suspension

Luye Pharma Group has announced that the US Food and Drug Administration (FDA) has approved the company's ERZOFRI (paliperidone palmitate) extended-release injectable suspension, for treating schizophrenia in adults and for treating schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants.

Drug Discovery & Development | 30/07/2024 | By Aishwarya |  850

Innovent and WeComput to Accelerate AI-Driven Drug Discovery and Development

Innovent Biologics, Inc. has forged a strategic partnership with WeComput to jointly advance the construction and improvement of Innovent Biologics' Artificial Intelligence for Drug Discovery platform.

Drug Discovery & Development | 26/07/2024 | By Aishwarya |  654

Sun Pharma Gets US FDA Approval for LEQSELVI for Treatment of Severe Alopecia Areata

Sun Pharmaceutical Industries Ltd. has announced that the US Food and Drug Administration (FDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata.

Drug Discovery & Development | 26/07/2024 | By Aishwarya |  1285